Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting ...

A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

Greenberg Traurig, LLP's London office has been shortlisted in three categories, including Best Client Service, Corporate Team of the Year, and Real Estate Team of the Year, at The Lawyer Awards 2025.

LivePerson, Inc. is providing confirmatory notice, in compliance with the requirements of Nasdaq Listing Rule 5635(c)(4), of recent grants of equity-based incentive awards that LivePerson made under ...